NYSE:GKOS - Glaukos Stock Price, Forecast & News

Glaukos trades on the New York Stock Exchange (NYSE) under the ticker symbol "GKOS."

Glaukos Corp (NYSE:GKOS) released its quarterly earnings data on Wednesday, November, 6th. The medical instruments supplier reported ($0.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.17) by $0.07. The medical instruments supplier had revenue of $58.51 million for the quarter, compared to analyst estimates of $56.96 million. Glaukos had a negative return on equity of 4.01% and a negative net margin of 8.60%. The firm's revenue for the quarter was up 33.2% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.17) EPS. View Glaukos' Earnings History.

Glaukos is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Glaukos.

Glaukos will be holding an earnings conference call on Thursday, February 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

9 brokerages have issued twelve-month price objectives for Glaukos' stock. Their forecasts range from $58.00 to $80.00. On average, they expect Glaukos' stock price to reach $68.89 in the next twelve months. This suggests a possible upside of 9.7% from the stock's current price. View Analyst Price Targets for Glaukos.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last year. There are currently 2 sell ratings, 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Glaukos.

Media headlines about GKOS stock have been trending neutral this week, according to InfoTrie Sentiment. The research firm identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Glaukos earned a media sentiment score of 0.4 on InfoTrie's scale. They also assigned media stories about the medical instruments supplier a news buzz of 9.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Glaukos.

Some companies that are related to Glaukos include Novocure (NVCR), ABIOMED (ABMD), Hill-Rom (HRC), Penumbra (PEN), Haemonetics (HAE), Globus Medical (GMED), Tandem Diabetes Care (TNDM), Integra Lifesciences (IART), ICU Medical (ICUI), Nevro (NVRO), NuVasive (NUVA), Cantel Medical (CMD), Irhythm Technologies (IRTC), Merit Medical Systems (MMSI) and Inspire Medical Systems (INSP).

Based on aggregate information from My MarketBeat watchlists, some companies that other Glaukos investors own include PTC Therapeutics (PTCT), Alibaba Group (BABA), Paypal (PYPL), Twilio (TWLO), Caterpillar (CAT), Boeing (BA), Canopy Growth (CGC), Baidu (BIDU), DexCom (DXCM) and NVIDIA (NVDA).

(GKOS) raised $76 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs acted as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.

Glaukos' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (9.83%), Fred Alger Management LLC (6.14%), William Blair Investment Management LLC (5.43%), Janus Henderson Group PLC (4.74%), Artisan Partners Limited Partnership (3.31%) and FMR LLC (2.97%). Company insiders that own Glaukos stock include Chris M Calcaterra, Gilbert H Kliman, Jonathan Silverstein, Joseph E Gilliam, Orbimed Advisors Llc, Thomas William Burns and William J Phd Link. View Institutional Ownership Trends for Glaukos.

GKOS stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Victory Capital Management Inc., Victory Capital Management Inc., William Blair Investment Management LLC, Man Group plc, Renaissance Technologies LLC, Bank of America Corp DE and Cubist Systematic Strategies LLC. Company insiders that have sold Glaukos company stock in the last year include Chris M Calcaterra and Joseph E Gilliam. View Insider Buying and Selling for Glaukos.

GKOS stock was bought by a variety of institutional investors in the last quarter, including Interwest Venture Management Co., Baillie Gifford & Co., Jennison Associates LLC, Janus Henderson Group PLC, Fred Alger Management LLC, Artisan Partners Limited Partnership, FMR LLC and State Street Corp. View Insider Buying and Selling for Glaukos.

Shares of GKOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of GKOS stock can currently be purchased for approximately $62.81.

Glaukos has a market capitalization of $2.29 billion and generates $181.28 million in revenue each year. The medical instruments supplier earns $-12,950,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. Glaukos employs 437 workers across the globe.View Additional Information About Glaukos.

The official website for Glaukos is http://www.glaukos.com/.

Glaukos' mailing address is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672. The medical instruments supplier can be reached via phone at 949-367-9600 or via email at [email protected]